European Recommendations for Transitioning the Care of Patients With Multiple Myeloma Treated With B‐Cell Maturation Antigen Bispecific Antibodies From Academic Hospitals to Community‐Based Centers and for Outpatient Step‐Up Dosing

Documenti analoghi

• Correction to “B‐cell Maturation Antigen‐Based Therapies Post‐Talquetamab in Relapsed or Refractory Multiple Myeloma”
  Pubblicazione: (2025)
• Early Free Light‐Chain Suppression as a Prognostic Marker in Relapsed and Refractory Myeloma Patients Treated With BCMA‐Directed CAR‐T Cells
  di: Tim Richardson, et al.
  Pubblicazione: (2025)
• The Role of Radiotherapy for Patients With Multiple Myeloma in the Modern Era: A Real World Single‐Centre Experience
  di: Dipal Mehta, et al.
  Pubblicazione: (2025)
• Prevalence of CCR7‐Positive CD8 T Cells as a Prognostic Factor in B‐Cell Maturation Antigen ‐Targeted Chimeric Antigen Receptor T Cell Therapy
  di: Yoshiaki Marumo, et al.
  Pubblicazione: (2025)
• IgG Lambda Myeloma Presented With Haemophagocytic Lymphohistiocytosis (HLH) Successfully Treated With VTD Induction and Melphalan Autograft
  di: Ke Xu, et al.
  Pubblicazione: (2025)